Parabilis Medicines, Inc.

Prior to the IPO, the Company received aggregate gross proceeds of $ 811.8 million from sales of convertible preferred stock, $ 15.0 million from borrowings under a term loan, and $ 50.0 million of gross proceeds from the issuance of a SAFE .

SEC original ↗Parabilis Medicines, Inc. — 10-Q Quarterly report10-QAug 13, 2026

Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its cash needs through a combination of equity offerings, debt or royalty financings, and collaborations.

SEC original ↗Parabilis Medicines, Inc. — 10-Q Quarterly report10-QAug 13, 2026

Significant estimates reflected within these condensed consolidated financial statements include the estimated fair value of the Company s common stock utilized in the determination of stock-based compensation expense prior to the IPO, the determination of the incremental borrowing rate for leases, the estimated fair value of the convertible preferred stock and SAFE, revenue recognition, as well as accrued research and development expenses.

SEC original ↗Parabilis Medicines, Inc. — 10-Q Quarterly report10-QAug 13, 2026

The expected dividend yield is zero, because the Company has never paid cash dividends on common stock and does not expect to pay any such dividends in the foreseeable future.

SEC original ↗Parabilis Medicines, Inc. — 10-Q Quarterly report10-QAug 13, 2026

Net Loss Per Share Basic net loss per common share is calculated by dividing net loss adjusted for cumulative dividends on convertible preferred stock accrued during the period, whether or not declared, and the value of any deemed dividends resulting from down-round adjustments to convertible preferred stock, where applicable, by the weighted-average number of shares of common stock outstanding during the period, without consideration of potentially dilutive securities.

SEC original ↗Parabilis Medicines, Inc. — 10-Q Quarterly report10-QAug 13, 2026

Net loss per share for each series of common stock issued is the same as they are entitled to the same liquidation and dividend rights.

SEC original ↗Parabilis Medicines, Inc. — 10-Q Quarterly report10-QAug 13, 2026

“This quarter marked meaningful progress toward our long-term vision as we continued advancing zolucatetide across multiple Wnt/β-catenin-driven diseases, including toward planned registrational development in desmoid tumors, while also extending the reach of our Helicon platform through our strategic research collaboration with Regeneron focused on developing Antibody-Helicon Conjugates, said Mathai Mammen, M.

SEC original ↗Parabilis Medicines, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2026

The investigational therapy is being evaluated as a “pipeline in a product” across multiple Wnt/β-catenin-driven diseases, with promising early clinical data demonstrating its potential in desmoid tumors, with familial adenomatous polyposis (FAP) and adamantinomatous craniopharyngioma (ACP) as potential genetically anchored expansion opportunities.

SEC original ↗Parabilis Medicines, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2026

• Announced a strategic collaboration with Regeneron Pharmaceuticals, Inc.

SEC original ↗Parabilis Medicines, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2026

, as Chief Business & Strategy Officer, and Tom Kotarakos as Chief Financial Officer • Appointed Alan M.

SEC original ↗Parabilis Medicines, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2026

Beyond zolucatetide, Parabilis is advancing additional Helicon-based programs focused on other challenging targets where we believe our medicines could have life-altering impact.

SEC original ↗Parabilis Medicines, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2026

Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks and uncertainties that could negatively affect the Company’s business, operating results, financial condition and stock value.

SEC original ↗Parabilis Medicines, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2026

Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining the Company’s intellectual property protections; and risks related to the competitive landscape for the Company’s product candidates; as well as other risks and uncertainties described in greater detail in “Risk Factors,” in the Company’s most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission.

SEC original ↗Parabilis Medicines, Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2026

Any forward-looking statements in this presentation are based on management's current expectations and beliefs, and are subject to a number of risks and uncertainties that could negatively affect the Company's business, operating results, financial condition and stock value.

SEC original ↗Parabilis Medicines, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 13, 2026

Refer to the Company's Risk Factors in the Company's most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the Securities and Exchange Commission.

SEC original ↗Parabilis Medicines, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 13, 2026

Legal Proceedings 44 Item 1A.

SEC original ↗Parabilis Medicines, Inc. — 10-Q Quarterly report10-QAug 13, 2026

These statements involve known and unknown risks, uncertainties, and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

SEC original ↗Parabilis Medicines, Inc. — 10-Q Quarterly report10-QAug 13, 2026